ALIGOS THERAPEUTICS INC (ALGS)

US01626L1052 - Common Stock

39.84  +1.49 (+3.89%)

After market: 40.3388 +0.5 (+1.25%)

ALIGOS THERAPEUTICS INC

NASDAQ:ALGS (12/20/2024, 8:00:00 PM)

After market: 40.3388 +0.5 (+1.25%)

39.84

+1.49 (+3.89%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%70.05%
Sales Q2Q%-60.82%
CRS99
6 Month253.35%
Overview
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Ins Owners3.75%
Inst Owners65.59%
Market Cap143.03M
Shares3.59M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts84.44
Short Float %9.96%
Short Ratio0.71
IPO10-16 2020-10-16
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ALGS Daily chart

Company Profile

Aligos Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 68 full-time employees. The company went IPO on 2020-10-16. Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The firm discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. The company is also progressing oligonucleotide projects for MASH. The company is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.

Company Info

ALIGOS THERAPEUTICS INC

One Corporate Dr., 2Nd Floor, 2nd Floor

South San Francisco CALIFORNIA 94080

P: 18004666059

CEO: Lawrence M. Blatt

Employees: 68

Website: https://www.aligos.com/

ALGS News

News Image10 days ago - Aligos TherapeuticsAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Image10 days ago - Aligos TherapeuticsAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage...

News Imagea month ago - Aligos TherapeuticsAligos Therapeutics to Present at Investor Conferences in December
News Imagea month ago - Aligos TherapeuticsAligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
News Imagea month ago - Aligos TherapeuticsAligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...

News Image2 months ago - Aligos TherapeuticsAligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

ALGS Twits

Here you can normally see the latest stock twits on ALGS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example